Details der Publikation - Ensayo de fase 3, aleatorizado y abierto, de lenalidomida/dexametasona, con o sin elotuzumab, en el mieloma múltiple en recidiva o resistente al tratamiento // A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

Ensayo de fase 3, aleatorizado y abierto, de lenalidomida/dexametasona, con o sin elotuzumab, en el mieloma múltiple en recidiva o resistente al tratamiento // A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma : Ensayo de fase 3, aleatorizado y abierto, de lenalidomida/dexametasona, con o sin elotuzumab, en el mieloma múltiple en recidiva o resistente al tratamiento // A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 08. Aug. Zur Gesamtaufnahme - year:2022

Sprache:	Spanisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Mieloma múltiple en recidiva o resistente al tratamiento // Relapsed or Refractory Multiple Myeloma MedDRA version: 13.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) Phase: Phase 3 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 13-06-2011, Last updated: 2022-11-24

ICTRP ID:	EUCTR2010-020347-12-ES CA204004 2010-020347-12-HU

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG006304591

Internformat


LEADER	01000caa a22002652 4500
001	CTG006304591
003	DE-627
005	20230425165546.0
007	cr uuu---uuuuu
008	210507s2022 xx \|\|\|\|\|o 00\| \|\|spa c
035			\|a (DE-627)CTG006304591
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2010-020347-12-ES
035			\|a (UBBS_Klinische_Studien_WHO)CA204004
035			\|a (UBBS_Klinische_Studien_WHO)2010-020347-12-HU
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a spa
245	1	0	\|a Ensayo de fase 3, aleatorizado y abierto, de lenalidomida/dexametasona, con o sin elotuzumab, en el mieloma múltiple en recidiva o resistente al tratamiento // A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma \|b Ensayo de fase 3, aleatorizado y abierto, de lenalidomida/dexametasona, con o sin elotuzumab, en el mieloma múltiple en recidiva o resistente al tratamiento // A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 13-06-2011, Last updated: 2022-11-24
650		4	\|a Medical Condition: Mieloma múltiple en recidiva o resistente al tratamiento // Relapsed or Refractory Multiple Myeloma MedDRA version: 13.1Level: PTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 08. Aug.
773	1	8	\|g year:2022 \|g day:08 \|g month:08
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-020347-12 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 08 \|c 08

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände